Physicians' Academy for Cardiovascular Education

CVD and stroke in Asia: Lipid management

News - Dec. 22, 2012

2012 Updated. A 72 slide/lecture kit with a focus on the burden of cardiovascular disease and stroke in Asia. With updates on lipid management:
  • CV Risk and Lipids in Asia: Epidemiology (17 slides)
  • Cholesterol Lowering and CV Risk: Meta-analyses (10 slides)
  • Statin Landmark Trials Across the Spectrum of Risk: Primary CV Prevention (9 slides)
  • Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention (24 slides)
  • Landmark Statin Trials Across the Spectrum of Risk: Secondary Stroke Prevention (12 slides)

CV Risk and Lipids in Asia: Epidemiology

Slide lecture program (17 slides): View & Download

  1. The Burden of CVD in Asia: Stroke Deaths by Country
  2. The Burden of CVD in Asia: CHD Deaths by Country
  3. Age-Standardized Stroke and CHD Death Rates by Country
  4. Stroke Type in China
  5. Projected Stroke and CHD Increase to 2030
  6. Burden of Diabetes in Asia 
  7. High Cumulative Incidence of Stroke in Asians With Type 2 Diabetes
  8. Increase in Age-Standardized Mean Total Cholesterol Levels in East and Southeast Asia and Pacific Region
  9. Association of Stroke Mortality With Usual Total Cholesterol by Age
  10. Relationship of Cholesterol Level to CV Mortality in Asians
  11. Association Between Usual Cholesterol Level and CHD Death or Nonfatal MI
  12. Association Between Usual Cholesterol Level and Stroke
  13. Association Between Usual Cholesterol Level and Ischemic Stroke
  14. Association Between Usual Cholesterol Level and Hemorrhagic Stroke

Cholesterol Lowering and CV Risk: Meta-analyses

Slide lecture program (10 slides): View & Download

  1. On-Treatment LDL and CHD Events in Statin Trials
  2. Second Cycle of the CTT Meta-analysis: Proportional Effects on Major Vascular Events 
  3. Second Cycle of the CTT Meta-analysis: More vs Less Statin
  4. Second Cycle of the CTT Meta-analysis: Statin vs Control
  5. Meta-analysis of Statin Trials and Fatal and Nonfatal Stroke
  6. Meta-analysis of Statin Trials and Stroke Mortality
  7. Stroke Risk and LDL Lowering in Statin Trials
  8. Second Cycle of the CTT Meta-analysis: Proportional Effects on Cause-Specific Mortality
  9. Meta-analysis of Statin Trials: Effect of Intensive LDL-C Lowering vs Standard Statin Therapy on Fatal and Nonfatal Stroke

Statin Landmark Trials Across the Spectrum of Risk: Primary CV Prevention

Slide lecture program (9 slides): View & Download

  1. Over Time Additional Risk Factors Can Progress
  2. ASCOT LLA Trial of Statin in Hypertensive Patients With Additional Risk Factors
  3. ASCOT LLA Primary End Point: Nonfatal MI and Fatal CHD
  4. ASCOT LLA Secondary End Point: Fatal and Nonfatal Stroke
  5. HPS: Effects of Statin on Major Coronary Events and Stroke in Diabetic and Nondiabetic Patients
  6. CARDS: Effect of Atorvastatin on the Primary End Point—Major CV Events Including Stroke
  7. CARDS: Component End Points
  8. JUPITER Trial of Statin in People With Elevated CRP: Primary End Point

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention

Slide lecture program (24 slides): View & Download

  1. TNT: Study Design Treating to New Targets
  2. TNT Primary Efficacy Outcome Measure: Major Cardiovascular Events
  3. TNT: Primary and Secondary Efficacy Outcomes
  4. TNT: Time to First Fatal or Nonfatal Stroke 
  5. TNT: Safety Profile
  6. IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering): Study Design
  7. IDEAL: Primary and Secondary End Points
  8. Effects of Atorvastatin 80 mg/d vs Simvastatin 20 to 40 mg/d on Any CV Event
  9. MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering): Study Design
  10. MIRACL: Primary Efficacy Measure— Time to First Event
  11. MIRACL: Stroke
  12. PROVE IT-TIMI (Pravastatin or Atorvastatin Evaluation and Infection Therapy– Thrombolysis in Myocardial Infarction) 22: Study Design
  13. PROVE IT: Primary End Point (All-Cause Death or Major CV Events in All Randomized Subjects)
  14. PROVE IT-TIMI 22: Intensive Therapy With Statins in Patients With ACS: Early and Long-term Benefits
  15. Safety of Atorvastatin 80 mg in Clinical Trials
  16. Overview of Adverse Events for Atorvastatin 10 mg and 80 mg and Placebo
  17. TNT: Changes in LDL-C by Treatment 
  18. PROVE IT: Reductions in Major Cardiac End Points
  19. Effect of Intensive Statin Therapy on Clinical Outcomes
  20. Long-term Statin Treatment in IDEAL Maintained Benefit Over 5 Years
  21. MIRACL: Secondary End Points
  22. Association of Dyslipidemia and myocardial Infarction Risk: INTERHEART
  23. ASCOT CRP Analysis

Landmark Statin Trials Across the Spectrum of Risk: Secondary Stroke Prevention

Slide lecture program (12 slides): View & Download

  1. Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
  2. SPARCL Trial of Secondary Stroke Prevention: Study Design
  3. SPARCL Primary End Point: Time to Fatal or Nonfatal Stroke
  4. SPARCL Secondary End Point: Time to Major Coronary Event
  5. SPARCL: Benefit/Risk
  6. Effect of Atorvastatin on Stroke In SPARCL Patients with Diabetes
  7. SPARCL: Stroke in Patients With Carotid Stenosis
  8. SPARCL: Carotid Endarterectomy in Patients with Carotid Stenosis
  9. SPARCL: Prespecified and Post-Hoc Analyses
  10. SPARCL: Ischemic and Hemorrhagic Stroke Post hoc Analysis
  11. SPARCL: Multivariable Cox Regression Model Baseline Characteristics

Share this page with your colleagues and friends: